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1. Introduction
1.1. Nasal sarcoidosis
Lupus  pernio  was  first  described  by  Kreibich  and  Kraus  in  1908.  [6]  Pathognomic  for
sarcoidosis,  Lupus pernio is  a  plaque-like lesion that  is  usually  swollen,  scaly or  shiny.
Typically, it occurs on the nose, cheeks, lips or ears. [7] Lupus pernio is most commonly
observed in African-American women [8] and approximately 20% of all sarcoidosis patients
with the lesion have co-morbid upper respiratory tract disease. [9] The skin lesion often
involves  the  nasal  mucosa and sometimes the  underlying cartilage  and nasal  bones  are
destroyed. [7]
Nasal disease is usually associated with sinus disease. [10, 11] However, the clinical manifes‐
tations of nasal granulomas differ from sinus granulomas. Nasal mucus membrane granulo‐
mas may cause nasal obstruction, [11] epistaxis, crusting, rhinorrhea, post-nasal drip, pain and
anosmia. [3] Obstruction is usually the most common presenting symptom when polypoid
granulomatous lesions involve the nasal septum and the inferior turbinate. Fergie and
colleagues retrospectively reviewed eight patients with nasal sarcoidosis and found that
epiphora was present in 4 patients. [12]
On examination, the nasal mucosa is usually hypertrophic, erythematous and granular. It may
also contain polyps, masses and/or asymmetric crust-like patches. The nasal bones may
demonstrate a variety of radiographic abnormalities. [9, 10] Septal perforation is rare but
granulomatous inflammation of the nasal cartilage (figure 2) may result in the classic “saddle
nose” deformity. [13] Occasionally, granulomatous lesions may erode through the hard or soft
palate, creating intraoral lesions or oral-nasal fistulae. [14]
© 2013 Morgenthau; licensee InTech. This is an open access article distributed under the terms of the
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Figure 1. Sarcoidosis patient with Lupus Pernio.
 
Figure 2. Bronchcoscopic appearance of endobronchial sarcoidosis demonstrating nodules and inflamed mucosa that
narrows the right upper lobe bronchus.
2. Sinus sarcoidosis
The symptoms of nasal obstruction and chronic sinusitis often occur in patients concomitantly.
[10, 11] The most common symptoms associated with sarcoidosis of the sinuses are recurrent
infections, epistaxis, periorbital tenderness, post-nasal drip and headache. [15] Patients with
sarcoidosis of the sinuses usually have involvement of multiple organ systems. [11] Sarcoidal
lesions in the sinus mucosa are generally similar to those found in the nasal mucosa. Exami‐
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nation often demonstrates erythematous, friable, hypertrophied mucosa. Crusting, studding,
plaque-like changes or polyps may also be visualized. Rarely, granulomatous lesions extend
out of the sinuses and into the orbit, resulting in proptosis and/or decreased unilateral visual
acuity. [16] Sarcoidosis of the sinuses is generally a chronic and recalcitrant form of the disease
that requires prolonged systemic therapy. [6, 17, 18]
3. Laryngeal sarcoidosis
The epiglottis, aryepiglottic folds, arytenoids, false cords and subglottis are the most com‐
monly affected regions in the larynx. The true vocal cords are relatively devoid of lymphatic
tissue and are rarely ridden with disease. [19] Granulomatous involvement of the larynx may
cause life-threatening stridor or dysphagia. [10] On examination, the involved laryngeal
mucosa is typically pale pink, granular and edenomatous. Lesions vary in their size and shape.
Localized submucosal induration, punctate nodules or polypoid masses may be present. In
one review of 40 patients with laryngeal sarcoidosis, the presenting symptoms were: dyspha‐
gia (85%), hoarseness (63%), dyspnea or stridor (47%) and cough (13%). [20] Ulceration of the
mucosa is rare. Patients also present with hoarseness, dysphonia, cough, dyspnea, a sensation
of a lump in the throat and obstructive sleep apnea. [21]
Hoarseness is typically caused by granulomatous laryngitis. However, laryngeal sarcoidosis
may cause hoarseness by two additional mechanisms. [22, 23] The first involves granuloma‐
tous infiltration of the vagus nerve, resulting in a polyneuropathy. Limited data suggests that
vagal polyneuropathy is rare [24] and if present, is typically associated with other cranial
neuropathies. [21] In rare cases, hoarseness may result from mediastinal lymphadenopathy
that compresses the recurrent laryngeal nerve, resulting in vocal cord paralysis. The left
recurrent laryngeal nerve is affected in more than 95% of cases. [21, 25] The predilection for
left-sided injury results from the longer and more vulnerable course of the left recurrent
laryngeal nerve through the mediastinum.
In one report, a young female presented with daytime hypersomnolence and snoring. [26]
Nasopharyngoscopy demonstrated an irregularly shaped and narrowed subglottis. Subse‐
quent biopsy confirmed the presence of non-caseating granulomas. The patient was diagnosed
with obstructive sleep apnea, secondary to laryngeal sarcoidosis. To determine the prevalence
and risk factors for obstructive sleep apnea in sarcoidosis patients, 83 patients with sarcoidosis
were prospectively evaluated. [27] The Epworth Sleepiness Scale was used to assess enrolled
patients. A control group of 91 patients were similarly screened. Patients with a positive sleep
questionnaire were referred for sleep studies. A total of 14 sarcoidosis patients (17%) were
found to have sleep apnea, which was significantly higher than in the control group where
3/91 were found to have obstructive disease (3%, p < 0.001). [27] Lupus pernio was significantly
more frequent in the sleep apnea group. [27] Although granulomatous laryngitis may be
associated with obstructive sleep apnea, obstructive sleep apnea in patients with sarcoidosis
usually results from obesity secondary to the administration of chronic corticosteroids.
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4. Tracheal sarcoidosis
Sarcoidal involvement of the trachea is rare [28] and the literature on tracheal sarcodosis is sparse.
Tracheal stenosis and dystonia are the primary manifestations that have been described. [28, 29]
Brandstetter and associates [30] described a patient who complained of deteriorating voice
strength for 30 years and eventually, stridulent breathing that was refractory to corticosteriods.
In 1949, Lemoine described tracheal dystonia (tracheal collapse most pronounced on expira‐
tion) in sarcoidosis. Ellefsen detailed a 44-year-old female who complained of progressive
dyspnea for 4 years prior to admission to the hospital. [29] She eventually developed wheezing
and a severe nonproductive cough. Physical exam showed stridor and wheezing.
5. Bronchial sarcoidosis
Bronchial sarcoidosis was first described at autopsy by Bernstein and colleagues in 1929 and
subsequently on bronchcoscopy by Benedict and Castleman in 1941. [31] Numerous case series
have followed. [32-37] Granulomatous lesions typically occur in the bronchial submucosa. [37]
The bronchial mucosa often appears inflamed with small or large nodules containing granu‐
lomas. [37] (Figure 2) Granulomatous involvement of the bronchi may cause edema and/or an
endobronchial masses that results in reversible narrowing of the large airways. [33, 36, 37]
Irreversible narrowing, especially of the right middle lobe bronchus, results from cicatricial
stenosis. [33] Reversible or irreversible bronchial stenosis occurs more commonly in the
presence of end-stage pulmonary fibrosis. But bronchostenosis may occur in milder stages of
the disease. [33, 36, 37] Bronchial sarcoidosis may be isolated (one stenotic point) or diffuse
(multiple stenotic points) involving the lobar or segmental bronchi. Compressive mediastinal
and/or bronchopulmonary lymphadenopathy is rarely a cause of stenoses at these locations
within the airway. [38, 39]
Patients with bronchial sarcoidosis present with dyspnea, cough and wheezing that is often
misdiagnosed as asthma. [10] The symptoms generally progress and are refractory to bron‐
chodilators and inhaled corticosteroids. Bronchial sarcoidosis is suggested by obstructive
airways disease (a reduced ratio of forced expiratory volume in 1 second [FEV1] to forced vital
capacity [FVC]) that may be accompanied by airways hyperreactivity on pulmonary function
tests. Bronchoscopic inspection of the airways with or without biopsy of the parenchyma is
the most efficient method to confirm the diagnosis. Endobronchial involvement is common in
sarcoidosis. Endobronchial biopsy has a yield comparable to transbronchial biopsy and can
safely increase the diagnostic value of fiberoptic bronchoscopy. Performance of endobronchial
biopsies should routinely be considered in cases of suspected sarcoidosis.
6. Small airways sarcoidosis
Small airways disease is an underappreciated manifestation of pulmonary sarcoidosis. Region‐
al air trapping, indicative of small airways disease, may be visualized on expiratory HRCT [40]
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and newer imaging modalities such as hyperpolarized 3-H MRI, [41, 42] in patients with pulmo‐
nary sarcoidosis who have obstructive airways disease. Peripheral airway obstruction with
involvement of small airways may be caused by the formation of granulomas in a perilymphat‐
ic distribution along the bronchovascular bundles. [41, 43] Small airways dysfunction can be
measured by forced expiratory flow during the middle half of the forced expiratory curve
(MMEF25-75%), forced expiratory volume at 3 seconds (FEV3) ratio of the residual volume to the total
lung capacity (RV/TLC). In one study, the extent of air trapping on HRCT correlated significant‐
ly with RV/TLC and MMEF25-75%. [41, 43] In other studies, however, these physiologic measure‐
ments were highly variable and provided limited clinical information. [43-45]
Patients with small airways disease typically present with progressive dyspnea, cough and
wheeze. They may also exhibit stridulent breathing. Lung auscultation demonstrates wheez‐
ing, stridor or squeaks.
Skin of the Nose (Lupus Pernio)
Nares
Nasal Septum
Sinuses
Larynx
Vocal Cords
Trachea
Bronchi
Bronchioles
Table 1. Airway Involvement in Sarcoidosis
INFECTIOUS NON-INFECTIOUS
Tuberculosis Sarcoidosis
Atypical Mycobacterial Disease Wegener’s Granulomatosis
Syphilis Berylliosis
Leprosy Silicosis
Aspergillosis Hypersensitivity Pneumonitis
Histoplasmosis Lymphoma
Rhinoscleroma Cocaine
Coccidioidomycosis Churg-Strauss Syndrome
Toxoplasmosis Talc
Actinomycosis Lymphoid Interstitial Pneumonia
Cryptoccosis Rheumatoid Nodule
“Reprinted from Mukhopadhyay, S. et al…, Granulomatous Lung Disease: An Approach to the Differential Diagnosis.
May 2010, Vol. 134, No. 5, pp. 667-690 with permission from Archives of Pathology & Laboratory Medicine. Copyright
2010. College of American Pathologists.”
Table 2. Differential Diagnosis of Granulomatous Airways Diseases
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6.1. Airway Hyperreactivity (AHR)
The incidence of airway hyperreactivity (AHR) in sarcoidosis is highly variable. Airway
hyperreactivity has been observed in approximately 20%--50% of sarcoidosis patients. [46,
47] The statistical discrepancy probably results from different patient populations, study
designs and different definitions of sarcoidosis and AHR.
Airway hyperreactivity has important clinical and prognostic implications in sarcoidosis. [47]
Many patients with sarcoidosis exhibit normal pulmonary function and imaging but complain
of cough, dyspnea and wheeze. The wall of the airway may be narrowed and thickened as a
result of airway hyperreactivity or may collapse from an extrinsic pathologic process in the
lung. Airway hyperreactivity in sarcoidosis may also cause chronic airflow obstruction, which
has been associated with a poor prognosis. [47, 48] Fixed airway obstruction has been shown
to nearly double the risk of mortality. [47]
The prevalence of AHR, as demonstrated by a positive methacholine challenge test, is
significantly higher in sarcoidosis patients compared to normal controls. [1, 47] It is unclear
whether AHR is a physiologic manifestation of endobronchial sarcoidosis or reversible
airways disease in asthma. Rarely, asthma may be associated with sarcoidosis. [49] Airway
hyperreactivity in sarcoidosis and reversible airways disease in asthma may often be distin‐
guished by response to inhaled corticosteroids and/or beta-agonists. Asthmatic reactive
airways disease usually improves with these medications. But AHR in sarcoidosis commonly
requires treatment with oral corticosteroids. [33, 47] In many cases, AHR in sarcoidosis does
not improve with systemic corticosteroids.
Importantly, cough and wheeze secondary to AHR (as demonstrated by positive methacholine
challenge testing) should not be confused with cough and wheeze unrelated to AHR. Sarcoidal
cough and wheeze unrelated to AHR responds favorably to inhaled corticosteroids and/or beta-
agonists as does asthmatic cough and wheeze related to AHR. [47] Sarcoidal cough and wheeze
associated with AHR, however, may require treatment with oral corticosteroids, which is often
ineffective.
Several studies suggests that AHR in sarcoidosis correlates with both the degree of alveolitis and
angiotensin converting enzyme (ACE) levels in bronchoalveolar lavage (BAL) fluid and serum.
[50] In addition, higher serum ACE levels were found in sarcodosis patients with hyperreactivi‐
ty. [47] Finally, patients with AHR were more likely to have a positive endobronchial biopsy (9/9,
100%) compared to individuals without hyperreactivity (15/33, 45.5%), which suggests that AHR
is present in patients with more pronounced bronchial inflammation. [47]
6.2. Atelectasis
Lobar atelectasis may result from occlusion of a lobar bronchus. Bronchial obstruction may be
caused by one of two mechanisms: endobronchial stenosis [37] or rarely, by extrinsic compres‐
sion of the bronchus by enlarged lymph nodes. [51, 52] Atelectasis of the middle lobe is most
common but atelectasis of the right upper lobe has also been reported. [53] The middle lobe is
particularly susceptible to collapse because it has a small bronchial lumen, surrounded by many
lymph nodes and emerges at a right angle from the bronchus intermedius. Collapse of the right
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upper lobe may result in the radiographic S-sign of Golden, which is commonly associated with
cancer. Resolution of atelectasis is variable and it may occur even after several years. [54]
6.3. Fibrosis
Chronic, progressive, end-stage, pulmonary fibrosis with traction bronchiectasis, often
referred to as “honeycomb lung”, develops in approximately 25% of patients with chronic
pulmonary sarcoidosis. [40, 55] The condition is characterized by parenchymal fibrosis,
bronchiolectasis and enlarged, dilated air spaces. It usually occurs subpleurally within the
upper regions of the lung [40, 56] (figure 3). Oxygenation and ventilatory function are
impaired. Pulmonary function tests demonstrate severe restriction and gas transfer abnor‐
malities. Importantly, fibrosis characterized by a stage IV radiographic pattern, rarely re‐
sponds to treatment.
Figure 3. Sarcoidosis patient with granulomatous inflammation of the nasal cartilage
6.4. Bullous disease
Bullea (thin-walled air spaces in the lungs) may develop in patients with advanced pulmonary
sarcoidosis. Most sarcoidosis patients with bullous disease do not exhibit an extensive smoking
history and have airflow obstruction on pulmonary function tests. [10, 57] Dilatation and
rupture of bullae probably results from granulomatous bronchostenosis. [58] Bullae may
develop secondary to destruction of alveolar walls by alveolitis. [58] Bullous rupture may cause
pneumothorax.
Giant bullous changes in sarcoidosis may rarely cause the Vanishing Lung Syndrome. [59]
First described by Burke in 1937, the Vanishing Lung Syndrome describes an end stage of
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diffuse panacinar emphysema in which large air spaces develop, further impairing lung
function. [59] Miller and associates reported two cases of the Vanishing Lung Syndrome.
Postmortem analysis of the lungs demonstrated that the bullae were quite different from the
localized air spaces frequently seen in chronic pulmonary sarcoidosis. [10, 60]
6.5. Cavitary lung disease, bronchiectasis and mycetomas
Although the terms cyst and cavity have overlapping meanings and may be used interchange‐
ably, the technical definitions of these terms are different. Cysts are clearly defined air-
containing space surrounded by a relatively thin (≤ 4 mm) wall. A cavity, in contrast, is meant
to describe an air-containing lesion with a relatively thick (> 4 mm) wall or within an area of
a surrounding infiltrate or mass. The distinction is useful because there is a different diagnostic
approach to these anatomic structures. [61]
True cavitary lung disease, which results from necrosis of granulomatous areas creating
airspaces within thick walls or within a fibrotic mass, is rare in sarcoidosis. Sarcoidal cavities
must be differentiated from those associated with mycobacterial infection. The radiographic
cystic changes that occur in advanced sarcoidosis are typically consistent with saccular
bronchiectasis, rather than true cavitations. [57, 61] Saccular or cylindrical bronchiectasis likely
results from bronchial wall injury by granulomas, superimposed bronchial infection and radial
traction by peribronchial scar tissue. Colonization of the bronchiectatic sacs by Aspergillus sp.,
may result in the development of an aspergilloma. Patients with aspergillomas complicating
sarcoidosis may have life-threatening hemoptysis but, as a result of their advanced lung
disease, are usually high-risk surgical candidates. [62]
Intracavitary instillation of antifungal agents is an alternative treatment in patients with severe
pulmonary dysfunction who are poor operative risks. Percutaneous instillation of amphoter‐
icin B guided by CT scans may be effective for the treatment of aspergilloma. [63] In several
cases, the intervention has led to resolution of hemoptysis. [63] The response to percutaneous
injection of amphotericin B appears to be sustainable for several months. [63]
Israel and associates evaluated the role of surgery in 38 sarcoidosis patients with pulmonary
aspergillomas, 10 of whom were considered satisfactory operative candidates. [64] Satisfactory
candidates demonstrated a forced vital capacity greater than 50% predicted and a resting PaO2
greater than 80 mmHg. The indication for surgical resection in satisfactory and unsatisfactory
candidates was recurrent hemoptysis. Seven satisfactory and 7 unsatisfactory candidates
underwent segmental resection, lobectomy or bilobectomy. The authors did not specify the
type of procedure that each patient received. Patients were followed postoperatively for an
unspecified duration. Among the 7 satisfactory candidates who underwent resection, 1 patient
died from empyema immediately after surgery. Three of 7 patients with unsatisfactory
pulmonary function died of respiratory failure 1 month, 11 months and 27 months, respec‐
tively, after surgery. Twenty-one patients with poor pulmonary function did not have surgery.
Four patients died of recurrent hemorrhage 4 months to 3 years after discovery of the asper‐
gilloma. Eleven patients died of respiratory failure and 6 survived at the time of publication
(1982) although it is unclear when these patients were diagnosed with their aspergilloma. The
principle complications of surgical resection were prolonged air leaks, bronchopleural fistulae
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and empyema. The authors concluded that surgical resection should generally be avoided in
patients with bilateral disease and compromised pulmonary function. The indication for
surgery in all patients, especially those with poor pulmonary function, should be recurrent
hemoptysis because it may cause exsanguinating hemorrhage, which poses a greater risk to
the patient than surgical intervention. [64]
7. Imaging
Computed tomography (CT) is often the imaging method of choice for sarcoidosis of the upper
and lower respiratory tract. [40] Braun and associates analyzed the CT findings of 15 patients
with sinonasal sarcoidosis. [20] A spectrum of abnormalities were evaluated: nodular lesions
of the septum and/or inferior turbinates; mucosal thickening and complete or subtotal
opacification of the ethmoidal, maxillary and/or sphenoid sinuses; obstruction of the ostio‐
meatal units and of the upper part of the nasal cavities; turbinoseptal synechiae; destruction
or erosion of the turbinates, nasal bones, septum, ethmoid air cells and sphenoid sinus.
CT scan has a high sensitivity for detecting sarcoidosis of the larynx or trachea. [65] Typically,
the CT demonstrates stenosis of the larynx and trachea.
Airways sarcoidosis produces a variety of abnormalities on CT scan of the lungs. Several CT
studies performed at near residual volume (end expiration) have demonstrated air-trapping
in pulmonary sarcoidosis. [40, 66, 67] Davies and colleagues reported that air-trapping on
expiratory CT was present in 95% of 21 sarcoidosis patients and correlated with physiologic
obstruction by percentage predicted residual volume (RV)/ total lung capacity (TLC) (p < 0.05)
and percentage predicted maximal mid-expiratory flow rate between 25% and 75% of the vital
capacity (VC) (p < 0.05). [41] The CT may also demonstrate focal bronchial lesions, atelectasis,
bullous disease, fibrosis/honeycombing, cavitary lung disease, bronchiectasis (saccular or
cylindrical) and mycetomas
8. Physiology
The respiratory tract is typically divided into the upper and lower airways at the level of the
vocal cords. The physiology of obstruction to the upper airways depends on the location of
the obstruction (intrathoracic or extrathoracic) and whether it is fixed or variable within the
respiratory cycle. Granulomatous involvement of the larynx results in a fixed upper airway
obstruction. When tracheal sarcoidosis results in stenosis, it may cause a fixed upper airway
obstruction (figure 4) or a variable extrathoracic or intrathoracic obstruction (figure 4)
depending on whether it is located above (extrathoracic) or below (intrathoracic) the thoracic
inlet (level of the supra-sternal notch). In a fixed upper airway obstruction, there is flattening
of the inspiratory and expiratory limbs of the flow volume loop. A variable extrathoracic
obstruction causes flattening of the inspiratory portion of the flow volume loop, while a
variable intrathoracic obstruction causes flattening of the expiratory portion of the loop.
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Spirometry commonly indicates restrictive ventilatory dysfunction. At least 50% of patients
have concurrent obstructive airways disease, evidenced by a reduced ratio of forced expiratory
volume in 1 second (FEV1) to forced vital capacity (FVC). [2, 68] Airway hyperreactivity
assessed by methacholine challenge test occurs in 5-83% of patients. [47, 68]
Figure 4. Sarcoidosis patient with “honeycomb lung”.
TLC = Total Lung Capacity, RV = Residual Volume
Adapated with permission from Kavuru et al…Essentials of Pulmonary and Critical care Medicine. 5th Edition. Philadel‐
phia. Lippincott, Williams and Wilkins, 2005.
Figure 5. Flow volume loops demonstrating various types of airways obstruction.
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9. Bronchoscopy
The diagnosis of sarcoidosis is confirmed by histologic evidence of non-caseating, epitheliod
granulomas. Tissue is obtained from the upper airways by direct nasopharyngoscopy.
Transbronchial and/or mucosal biopsies of the lower airways may be obtained by bronchoco‐
scopy, the diagnostic procedure of choice for sarcoidosis.
10. Treatment
There are no controlled studies that examine the variety of therapeutic agents, which are
purported to be effective in the treatment of sarcoidosis. There is consensus by experienced
physicians that corticosteroids are the most efficacious medication. None of the other therapies
share this favorable level of support. Oral corticosteroids are given in the smallest possible
dose to limit their adverse effects. Since upper airways obstruction occurs in chronic sarcoi‐
dosis, ‘steroid-sparring’ medications may be administered simultaneously to reduce the
corticosteroid dose that would be needed if it is given for many months. Hydroxychloroquine
has been used with some success for cutaneous sarcoidosis. [69] Minocycline is also effective
for the treatment of skin lesions. [70, 71] Minocycline appears to inhibit metalloproteinases,
angiogenesis, apoptosis and in vitro granuloma formation. [68, 72]
The treatment of sinus and nasal sarcoidosis should be tailored to the specific organ system or
systems involved and to the extent of disease. [14, 16] Isolated sinonasal disease can be treated
by topical corticosteroids and/or intra-lesional steroid injections. [73] Nasal irrigations and
emollients may be used to ameliorate nasal crusting. Siltzbach and Teirstein used chloroquine
to treat 14 pataients with intrathoracic and cutaneous sarcoidosis. All of the patients showed
relative improvement in their cutaneous lesions and most exhibited radiographic improve‐
ment of their intrathoracic disease. Johns and colleagues used hydroxychloroquine, a drug
with less ocular toxicity, to treat mucosal lesions. [74] Patients taking hydroxychloroquine
must have an ophthalmic exam every 6 months. Hassid reported a patient with biopsy-proven
sarcoidosis of the paranasal sinuses who was successfully treated with hydroxychloroquine
200 mg orally, twice daily for one month and 200 mg per day for an additional 7 months. [75]
Despite these results, the overall response rate for antimalarial drugs is probably less than 50%
[76] and the drugs are often reserved for patients with cutaneous or sinonasal sarcoidosis, in
whom the response to treatment can be easily observed. [76]
Methotrexate may also be used for the treatment of cutaneous sarcoidosis. In several case
reports, skin lesions improved in patients who were treated with methotrexate 10 mg to
15 mg per week. [77] Although azathioprine has been commonly used as a corticosteroid-
sparing  agent  for  many  forms  of  sarcoidosis,  it  has  rarely  been  reported  for  the  treat‐
ment  of  skin  sarcoidosis.  [7]  Tumor  necrosis  factor-a  (TNF-a)  antagonists  have  been
reported to be useful in the treatment of sarcoidosis, including cutaneous sarcoidosis. [78]
Inflixamab appears to be the most efficacious of the biologics. It may be especially useful
in the treatment of lupus pernio. [78]
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The indication for surgical intervention of sinonasal granulomatous lesions is controversial.
While surgery may reduce symptoms, it does not eradicate or prevent recurrence of disease.
[14, 17, 79] Neville and associates evaluated 34 patients with sarcoidosis of the upper respira‐
tory tract, [9] 3 of whom, underwent submucous resection. In 2 of 3 patients the resection was
complicated by nasal septal perforation. Aubart and colleagues operated on 7 patients. [17]
Nasal and sinus involvement recurred in all of them and sinus symptoms worsened in 1 patient
after surgery. But two additional studies suggest that endoscopic sinus surgery may have a
therapeutic role in patients with nasal obstruction or chronic sinusitis caused by anatomic
blockage from sinonasal sarcoidosis. [18, 80] Removal of the obstructing lesion(s) may facilitate
improved sinonasal hygiene by permitting endoscopic debridement, nasal irrigation and
topical administration of medicines into the sinonasal tract. Surgical intervention should not
be used to treat patients with symptoms related to crusting, atrophy or bleeding. While surgery
may improve one’s quality of life by relieving severe symptoms and may even reduce the need
for oral steroids, it is almost never curative.
Laryngeal sarcoidosis may cause life-threatening upper airway obstruction. As a result, early
diagnosis and proper management is essential. The treatment of laryngeal sarcoidosis depends
on the severity of the symptoms. Asymptomatic patients do not require therapy. [5, 19, 81] But
close monitoring is warranted. It may be difficult to assess the efficacy of various treatment
modalities because spontaneous remissions of disease punctuate the natural evolution of
sarcodosis. [51, 67] Systemic corticosteroids are the mainstay of treatment for laryngeal
sarcoidosis, especially for impending laryngeal obstruction. [1, 10] Methotrexate has been used
with some success in the treatment of laryngeal sarcoidosis. One patient with granulomatous
laryngitis responded to treatment with azathioprine. Intra-lesional steroid injections of the
larynx for selected patients with well-circumscribed disease is modestly effective. [5, 21] When
the airway is compromised and stridor is present, emergent tracheostomy should be per‐
formed. [21] Tracheostomy may also be an appropriate for patients who develop marked
adverse effects from systemic corticosteroids. [82] Tracheostomy is often used as a temporizing
measure until corticosteroids are able to effectively reduce granulomatous inflammation.
Surgical intervention for laryngeal sarcoidosis is effective for patients with well-localized, life
threatening lesions. [5] Typically, the goals of surgery are to create an adequate airway, avoid
aspiration, avoid tracheostomy and preserve the voice. [5, 83] Low-dose external beam
radiation therapy (3000 rads during 6 weeks) has been utilized in selected patients. [5, 84] It is
generally reserved for patients in whom intra-lesional steroids or local excision of granulom‐
atous tissue are not feasible and/or in those who are refractory to or cannot tolerate systemic
corticosteroids. [5, 82]
Tracheal involvement in sarcoidosis is limited to the description of tracheal dystonia [29] and
tracheal stenosis. [29, 30] Brandstetter and colleagues used high-dose systemic corticosteriods
to treat a patient with tracheal stenosis. The patient failed to stabilize with the treatment but
ultimately underwent successful bronchoscopic tracheal dilatation. [30] Tracheal stents have
been used with limited success for tracheobronchial obstruction in pediatric patients. [85]
Patients with bronchostenosis respond poorly to treatment with systemic corticosteroids. [33,
37, 46, 47, 53] Fouty and associates used a flexible fiberoptic bronchoscope and a Fogarty
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embolectomy catheter to dilate multiple bronchial stenoses under direct vision. [86] The six
patients who underwent the procedure were symptomatic and refractory to corticosteroids.
All of them obtained subjective symptomatic benefit from the dilatation. Three of the patients
required repeated dilatation on a long-term basis. Complications from the procedure were
minimal. Collectively, these studies suggest that bronchial dilatation is a safe option for
sarcoidosis patients with stenoses who are refractory to systemic corticosteroids.
The majority of patients with sarcoidosis improve with therapy. However, 10-30% of patients
develop progressive pulmonary fibrosis, which may result in advanced airways disease such
as bronchiectasis, bullae and cavitation. Rarely, patients with bronchiectasis will improve with
corticosteroids, antibiotics and/or nonsteroidal anti-inflammatory medications. [87] If patients
do respond, it is generally short-lived. Bullectomies performed for bullous sarcoidosis may
improve pulmonary function and symptoms. [57, 58] Surgical resection of the cavity and
removal of the fungus ball is the mainstay of treatment for aspergilloma(s). [88] The primary
indication for resection is recurrent hemoptysis. Bronchial artery embolization is modestly
effective in inoperable patients. [89] Taken together, advanced involvement in sarcoidosis is
seldom responsive to medical therapy, moderately responsive to surgical therapy depending
on the type of underlying disease and has an ominous prognosis. Finally, sarcoidosis patients
with fibrotic lung disease and/or airways dysfunction often develop pulmonary hypertension,
which often has an unfavorable prognosis.
11. Summary
Sarcoidosis is a chronic granulomatous disease of undetermined etiology that can involve any
organ system within the body. Greater than 90% of patients with sarcoidosis have interstitial
lung disease. [2] But the upper and lower respiratory tract is also affected. Sarcoidosis is one
of a few interstitial lung diseases that involves the entire respiratory tract; beginning at the
nose and ending at the terminal bronchioles.
Although many patients are asymptomatic, most complain of dyspnea, cough and/or wheez‐
ing, Patients with sarcoidosis of the upper respiratory tract present with a variety of symptoms,
which are primarily determined by the anatomic location of the granulomatous inflammation
and/or scarring that may result from chronic disease. The diagnosis of upper or lower
respiratory tract disease is frequently ascertained by bronchoscopy.
Computed tomography (CT), the imaging method of choice for sarcoidosis of the upper and
lower respiratory tract, may demonstrate lesions within the sinonasal tract, larynx and trachea,
large and small airways or parenchyma. It may also reveal mediastinal and/or hilar lympha‐
denopathy.
The physiology of airways obstruction depends on the location of the obstruction (intrathoracic
or extrathoracic) and whether it is fixed or variable within the respiratory cycle. Granuloma‐
tous involvement of the larynx results in a fixed upper airway obstruction. Tracheal sarcoidosis
may cause a fixed upper airway obstruction, or a variable extrathoracic or intrathoracic
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obstruction, depending on whether the lesion is located above (extrathoracic) or below
(intrathoracic) the thoracic inlet (level of the supra-sternal notch).
Patients with pulmonary sarcoidosis may exhibit obstructive, restrictive, restrictive and
obstructive, or gas transfer abnormalities. Corticosteroids are the mainstay of therapy for
upper respiratory tract disease. However, other immunosuppressive treatments may be
effective for the treatment of skin and sinonasal sarcoidosis. Patients with endobronchial or
tracheal stenoses who are refractory to steroid therapy may derive some benefit from me‐
chanical dilatation of the airways. [86] Surgical intervention may be required for treatment of
bullous sarcoidosis and aspergilloma. [57, 58]
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